Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Coixenolide is a fatty acid ester isolated from coix seeds (Coix lacryma-jobi Linn.). It exhibits anti-inflammatory, anti-tumor, and pain-reducing activities. It stimulates the lung, heart, striated, and smooth muscles at low doses, while inhibiting at high doses, and dilates pulmonary veins to improve pulmonary blood circulation. Coixenolide also affects the synthesis level of phosphoglucose isomerase and α-phosphoglucomutase, and has a depressant effect on tumor cells by inhibiting NF-κB-dependent transcription. It is being investigated for its therapeutic potential, including in severe traumatic brain injury, and can also be used as a nutraceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on coixenolide.